TABLE 2.

Multivariable regression analyses predicting biochemical recurrence, metastatic recurrence and prostate cancer specific mortality for men presenting with high-risk features undergoing radical prostatectomy (1992–2010)

	Biochemical recurrence			Metastatic recurrence			Prostate cancer mortality
Variable	Hazard ratio	95% CI	P	Hazard ratio	95% CI	P	Hazard ratio	95% CI	P
PSA risk (0–10 referent)
> 10–20	1.55	(1.18–2.0)	0.002	1.38	(0.86–2.2)	0.2	1.14	(0.66–2.0)	0.6
> 20	2.48	(1.84–3.3)	< 0.001	1.94	(1.14–3.3)	0.014	1.73	(0.99–3.0)	0.055
Clinical stage risk (cT1–cT2a referent)
cT2b	1.51	(1.15–2.0)	0.003	2.09	(1.28–3.4)	0.003	1.78	(1.01–3.1)	0.046
≥ cT2c	1.58	(1.17–2.1)	0.003	2.26	(1.38–3.7)	0.001	2.78	(1.63–4.8)	< 0.001
Biopsy Gleason risk (2–6 referent)
7	2.19	(1.64–2.9)	< 0.001	2.43	(1.40–4.2)	0.001	3.29	(1.67–6.5)	0.001
8–10	3.64	(2.60–5.1)	< 0.001	5.40	(2.97–9.8)	< 0.001	8.62	(4.32–17.2)	< 0.001